Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Saeki, Hidehisa; Nakagawa, Hidemi; Nakajo, Ko; Ishii, Taeko; Morisaki, Yoji; Aoki, Takehiro; S. Cameron, Gregory; O. Osuntokun, Olawale; Japanese Ixekizumab Study Group, the

doi:10.1111/1346-8138.13622

Public

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Shared by NobleBlocks on Oct 11, 2016 • 12:00 AM UTC

Authors:

Hidehisa Saeki

Hidemi Nakagawa

Ko Nakajo

Abstract

Abstract Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to evaluate the long‐term efficacy and safety of ixekizumab, a humanized, anti‐interleukin‐17A monoclonal antib...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!